Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (33)

I-02

Population Pharmacokinetic Analysis and Effects of Raltegravir In HIV positive and Healthy Individuals

Wednesday 10:15-11:45

I-03

Development of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic Fibrosis

Wednesday 10:15-11:45

I-16Julie Bertrand

Extensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients

Wednesday 10:15-11:45

I-30Margreke Brill

Cefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery.

Wednesday 10:15-11:45

I-39

Pharmacokinetics of doripenem in cerebrospinal fluid

Wednesday 10:15-11:45

I-46Christine Xu

Population Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV

Wednesday 10:15-11:45

I-60Paolo Denti

Population PK of Isoniazid in South African Adults.

Wednesday 10:15-11:45

II-17

Integrated Population Pharmacokinetic Model Development of Nevirapine for Mothers and Newborns including Healthy Male Volunteer Data

Wednesday 14:55-16:10

II-22Maria Garrido

Population Pharmacokinetics/Pharmacodynamics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in SOT Patients Infected with CMV

Wednesday 14:55-16:10

II-27Sylvain Goutelle

Comparison of Four Renal Function Estimator-Based Models for the Prediction of Gentamicin Concentrations in Geriatric Patients by Use of Nonparametric Population Approach

Wednesday 14:55-16:10

II-35Monia Guidi

Population Pharmacokinetics of Nevirapine in HIV-positive Patients

Wednesday 14:55-16:10

II-43

Population modelling of the pharmacokinetics of a mefloquine-artesunate treatment at the Thai-Myanmar border

Wednesday 14:55-16:10

II-46Arantxa Isla

Population Pharmacokinetics of Cefoxitin as a Prophylactic Antimicrobial Agent

Wednesday 14:55-16:10

II-60Dalia Khachman

Optimising ciprofloxacin dosing in intensive care patients based on pharmacodynamic target attainment

Wednesday 14:55-16:10

II-61David Khan

PKPD-modeling of time-kill curves from E. coli mutants exposed to ciprofloxacin

Wednesday 14:55-16:10

III-05Ryuji Kubota

A Novel Framework of Long-term Prediction of integrase inhibitors for treatment naïve patients

Thursday 09:50-11:05

III-36Elisabet Nielsen

PK/PD Indices of Antibiotics Predicted by Mechanism-Based PKPD Models

Thursday 09:50-11:05

III-63Dinko Rekic

Bilirubin – a biomarker of atazanavir exposure in HIV/AIDS patients

Thursday 09:50-11:05

IV-04Andre Schäftlein

Comparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models

Thursday 15:05-16:20

IV-09

Applications of Population Pharmacokinetic Modeling during Phase2B to Support the Clinical Development of Dolutegravir (DTG, S/GSK1349572)

Thursday 15:05-16:20

IV-12Joe Standing

Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents

Thursday 15:05-16:20

IV-16Elin Svensson

Mega-model of nevirapine population pharmacokinetics

Thursday 15:05-16:20

IV-17

Applying of population PK-PD methods to analysis of viral dynamics of HIV/HCV-Coinfected Sustained Virological Responders and Nonresponders treated with PEG-IFN

Thursday 15:05-16:20

IV-18Ami Fazlin Syed Mohamed

Pharmacokinetic-Pharmacodynamic Modelling of Pre-existing and Emerging Resistance of Pseudomonas aeruginosa to Colistin

Thursday 15:05-16:20

IV-34Marta Valle

Effect of Ritonavir Concentrations on Atazanavir Pharmacokinetics: Population Pharmacokinetic Analysis

Thursday 15:05-16:20

IV-35Georgia Valsami

Assessment of dosage regimens of tigecycline in hospitalised patients

Thursday 15:05-16:20

IV-38Jan-Stefan van der Walt

The effect of nevirapine-based antiretroviral therapy on the population pharmacokinetics of artemether and dihydroartemesinin in HIV-infected adults

Thursday 15:05-16:20

IV-42Max von Kleist

A Mathematical Modelling Framework to Assess the Impact of Nevirapine-based Prophylaxis on vertical HIV Transmission

Thursday 15:05-16:20

IV-45Toshihiro Wajima

Pharmacokinetic/pharmacodynamic Modeling and Long-term Simulation of Dolutegravir (DTG, S/GSK1349572) in Integrase Resistant Patients with a Simple Viral Dynamic Model

Thursday 15:05-16:20

IV-54

Mechanism-based Modelling of the Antagonism between Polymyxin B and Levofloxacin against Pseudomonas aeruginosa using Mono- and Combination Therapy

Thursday 15:05-16:20

IV-57James Yates

Population PK/PD modelling of AZD9773 in patients with severe sepsis.

Thursday 15:05-16:20

IV-62Chao Zhang

Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Adults

Thursday 15:05-16:20

IV-66Simbarashe Peter Zvada

Population Pharmacokinetics of Isoniazid in Children with Pulmonary Tuberculosis

Thursday 15:05-16:20